Regeneron Blockade Leaves Biocon Facing 2027 Wait On US Eylea Biosimilar
Four Other Firms Also Facing Up To Injunctive Relief Ahead Of Infringement Trial
Executive Summary
Biocon has been handed a further setback in its attempts to launch a biosimilar to the market-leading Eylea in the US, after a US district court signed off on a permanent injunction against the Indian firm lasting until June 2027. Meanwhile, decisions on motions for preliminary injunctions against several other biosimilar sponsors are imminent.